Discontinued Operations - Schedule of discontinued operation in operations statement (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Discontinued operation operating expense
Net loss from discontinued operations before income taxes		$ (3,040,577)		$ (5,848,220)
Income tax expense	$ 0	(65,189)	$ 0	(65,189)
Net loss from discontinued operations		$ (3,105,766)		(5,913,409)
Discontinued Operations, Disposed of by Sale | Elusys Therapeutics business unit
Discontinued Operations
Revenue				6,699,200
Discontinued operation operating expense
Cost of revenues				2,161,601
Research and development				2,191,796
Selling, general and administrative				1,147,730
Amortization of intangible assets				1,091,250
Goodwill impairment loss				3,873,079
Intangible asset impairment loss				2,277,921
Change in fair value of contingent consideration				(177,354)
Total operating expenses				12,566,023
Loss from operations				(5,866,823)
Interest income				55,991
Other expense				(37,388)
Total non-operating gain				18,603
Net loss from discontinued operations before income taxes				(5,848,220)
Income tax expense				(65,189)
Net loss from discontinued operations				$ (5,913,409)